Friday, December 16, 2011

Researcher: J&J/Pharmacyclics Drug Could Be a Game-Changer

Take a bow, Johnson & Johnson (NYSE: JNJ ). It certainly appears the company
knew what it was doing last week when it made a deal for a Pharmacyclics
(NASDAQ: PCYC ) experimental cancer drug. The compound

No comments:

Post a Comment

LinkWithin

Related Posts Plugin for WordPress, Blogger...